
Antibody-drug conjugates (ADCs) are emerging as a transformative treatment option for patients with endometrial cancer, offering promising response rates and potential to overcome previous therapeutic limitations.


coremsg

Drs Ursula A. Matulonis and Kathleen N. Moore discuss the different aspects of ADCs in endometrial cancer, medications that are currently available, and promising HER2 ADCs.

Episode 1: Antibody-Drug Conjugates in Endometrial Cancer

exploring-antibody-drug-conjugates-a-promising-frontier-in-endometrial-cancer-treatment


Exploring Antibody-Drug Conjugates: A Promising Frontier in Endometrial Cancer Treatment
